AGXT and primary hyperoxaluria type 1: PH1 is associated with a deficiency or functional defect in alanine glyoxylate aminotransferase.508,509 Lumasiran, a siRNA drug that targets hydroxy acid oxidase 1 to reduce hepatic oxalate production, was the first drug approved for PH1.510 Nedosiran, another RNAi drug developed by Dicerna Pharmaceuticals that targets LDHA, is currently being evaluated for its efficacy in reducing oxalate production.330